Change of the inspiratory peak flow after bronchial dilatation on patients with median to severe chronic obstruktiv lung disease

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-000511-26-DE

Enrollment

Registered

2006-08-28

Start date

2006-05-23

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with median to severe chronic obstruktiv lung disease

Interventions

Product Name: Oxis Turbohaler 12 Mikrogramm Pulver zur Inhalation Pharmaceutical Form: Powder for nebuliser suspension INN or Proposed INN: Fomoterol Concentration unit: µg microgram(s) Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patienten median to severe COPD (FEV1 betwen 30 % and70 % of index value) age >40 years male /female Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: any other significant lung disease atopiea oder bronchial asthma other severe or uncompensated disease hypersensitivity against Formoterol or inhaled lactose gravidity nursing women

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess the feasibility of using the INCHECK device to measure the change in PIF after bronchodilatation in COPD;Secondary Objective: Coverage of the symptomatic changes after intake of a bronchodilatator and their relationship to the functional lung changes;Primary end point(s): better control of therapy with bronchialdilatator on patients with COPD	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026